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Alterations in motor functions are well-characterized fea-
tures observed in humans and experimental animals sub-
jected to thyroid hormone dysfunctions during development.
Here we show that congenitally hypothyroid rats display hy-
peractivity in the adult life. This phenotype was associated
with a decreased content of cannabinoid receptor type 1 (CB1)
mRNA in the striatum and a reduction in the number of bind-
ing sites in both striatumandprojection areas. These findings
suggest that hyperactivity may be the consequence of a thy-
roid hormone deficiency-induced removal of the endocan-
nabinoid tone, normally acting as a brake for hyperactivity at
the basal ganglia. In agreement with the decrease in CB1 re-
ceptor gene expression, a lower cannabinoid response, mea-
sured by biochemical, genetic and behavioral parameters,
was observed in the hypothyroid animals. Finally, both CB1
receptor gene expression and the biochemical and behavioral
dysfunctions found in the hypothyroid animals were im-
proved after a thyroid hormone replacement treatment.
Thus, the present study suggests that impairment in the en-
docannabinoid system can underlay the hyperactive pheno-
type associated with hypothyroidism. (Endocrinology 149:
2657–2666, 2008)
THYROID HORMONES (T3 and T4) play an importantrole in the development and metabolism of many
mammalian tissues. Most of the actions of these hormones
are mediated by the binding of T3 to specific nuclear recep-
tors that are ligand-dependent transcription factors, which
bind, in the target genes, to specific DNA sequences called
thyroid hormone response elements, and regulate transcrip-
tion initiation (1). Hence, the primary action of thyroid hor-
mone is to control the expression of a limited number of
genes in target cells, which ultimately will cause the phys-
iological effects attributed to this hormone. Thyroid hormone
receptors (TRs) are members of a large family of nuclear
proteins that includes the receptors for steroids, retinoids,
vitamin D3, peroxisomal proliferators, and receptors with no
recognized ligand known as orphan receptors (2).
The brain is an important target for thyroid hormone ac-
tion, particularly during late fetal and early postnatal peri-
ods, as shown by numerous clinical and experimental data
(3). In the rat brain, the expression of thyroid hormone re-
ceptors increases rapidly after birth, reaching the highest
value by d 6 of postnatal life (4). Consistent with these data,
thyroid hormone absence during the perinatal period leads
to a profound brain damage unless replacement therapy with
thyroid hormone is started very soon after birth. The con-
sequences of the lack of thyroid hormone include, among
others, a reduction in dendritic arborization, poor connec-
tivity among neurons, impaired myelin deposition, and al-
tered cell migration and synaptogenesis (3, 5).
The endocannabinoid system is a neuromodulatory sys-
tem, which plays an important role in cognitive, affective,
and motor functions in the brain (6). The basic components
of this system are the cannabinoid receptor type 1 (CB1) and
its endogenous ligands, anandamide and 2-arachidonoylg-
lycerol, which act as retrograde signaling molecules to reg-
ulate synaptic plasticity (reviewed in Ref. 7). The CB1 recep-
tor is a highly abundant G protein-coupled receptor, which
regulates, through multiple subtypes of Gi/o proteins, the
activity of adenylyl cyclase, voltage-activated calcium chan-
nels, potassium channels, and mitogen-activated kinases (8).
In addition to CB1 receptors, another closely related canna-
binoid receptor, the cannabinoid receptor type 2 (9), has been
cloned. The cannabinoid receptor type 2 receptor is mainly
expressed in immune cells and consequently mediates the
immunomodulating activities of the cannabinoids. The ex-
istence of additional, not-yet-characterized cannabinoid re-
ceptors in the brain has been postulated to fully understand
the activity of these substances (10). In addition to these basic
constituents of the endocannabinoid system, other important
components include enzymes and transporters implicated in
the metabolism of anandamide and 2-arachidonoylglycerol
(6).
The motor system is a target of cannabinoids as shown by
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the profound impact that cannabinoid agonists have on mo-
tor behavior and the high level of expression of CB1 receptor
in the basal ganglia and cerebellum (11). In the basal ganglia,
the CB1 receptor gene is expressed in the medium spiny
neurons of the striatum and the protein accumulates in the
presynaptic terminals of these neurons in the output nuclei,
globus pallidus, and reticular part of the substantia nigra (12,
13). In the cerebellum, both the mRNA and protein are abun-
dant (12, 13). It has been shown that the dopaminergic-
mediated hyperactivity is modulated by the endogenous
cannabinoid system (14–16). Removal of endogenous can-
nabinoid tone by selective blockade of CB1 receptor poten-
tiates dopaminergic-mediated hyperactivity. In addition, po-
tentiation of endocannabinoid transmission with the
anandamide uptake blocker AM404 reduces hyperlocomo-
tion mediated by dopamine D2 receptors (14).
Alterations in motor activities are also well-characterized
features of thyroid hormone dysfunctions during develop-
ment, in both humans and experimental animals (17). We
focused our attention in one of these features, motor hyper-
activity. In humans, between 50 and 70% of the patients with
resistance to thyroid hormone (RTH), a syndrome caused by
the dominant inheritance of a mutated form of the TR
isoform (18), fulfill during childhood the diagnosis criteria
for attention deficit with hyperactivity disorder (ADHD) (19,
20). In contrast, in the general population, only 2–5% of
school-age children meet these criteria. In experimental mod-
els, transient perinatal hypothyroidism (from the end of
pregnancy to weaning) causes attention-deficit and hyper-
active neurobiological symptoms in adult animals (21–24). In
congenital hypothyroidism (hypothyroidism induced in the
perinatal life and maintained chronically), conflicting evi-
dences regarding motor hyperactivity have been published
(25, 26). In the case of perinatal hyperthyroidism, both tran-
sient and chronic models have been associated with hyper-
activity in the adult life (26, 27). However, very little is known
relative to the possible genes regulated by thyroid hormone,
which could be implicated in the appearance of the hyper-
active phenotype, although it has been suggested that alter-
ations in the dopaminergic and noradrenergic systems can
underlay the effects of thyroid hormone (25, 28, 29).
All these data have prompted us to hypothesize that the
hyperactivity associated with hypothyroidism during devel-
opment may be derived from alterations of the endocan-
nabinoid system, which exerts a negative feedback that limits
dopaminergic hyperactivity. To test this premise, we ana-
lyzed the locomotor activity, the expression of the CB1 re-
ceptor gene, and the response to cannabinoids in congeni-
tally hypothyroid rats. Our results clearly show that chronic
congenitally hypothyroid animals are hyperactive in the
adult life and that this phenotype correlates with a decreased
expression of the CB1 receptor gene in the basal ganglia, as
shown by a lower content of transcripts in the striatum and
a lower ligand binding in the striatum and midbrain. Con-
sequently, a lower biochemical, genetic, and behavioral re-
sponse to cannabinomimetic drugs is observed in these an-
imals. Finally, the biochemical and behavioral parameters
altered in the hypothyroid rats can be clearly improved by
the administration of therapeutic doses of thyroid hormones.
Materials and Methods
Materials
HU210 [()-11-hydroxy-8-tetrahydrocannabinol-dimethylheptyl],
Win55212-2 [R-()-(2,3-dihydro-5-methyl)-3-[(morpholinyl)meth-
yl[pyrrolo[1,2,3-de]-1,4-benzoxazinyl] (1-naphthalenyl)methanone me-
sylate], and AM404 [N-(4-hydroxyphenyl] arachidonylamide) were
purchased from Tocris (Cookson, UK). SR141716A [N-(piperidin-1-yl)-
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4methyl-1H-pyrazole-3-
carboxamide hydrochloride] was a gift from Sanofi-Aventis (Montpel-
lier, France). [-32P]dCTP (3000 Ci/mmol) and [3H]SR141716A (53 Ci/
mmol) were purchased from Amersham Corp. (Buckinghamshire, UK)
and [35S]GTPS (1000 Ci/mmol) from NEN Life Science Products
(Boston, MA). GTPS, T4, T3, and 2-mercapto-1-methylimidazole were
purchased from Sigma Chemical Co. (St. Louis, MO). All other chem-
icals were reagent grade or molecular biology grade.
Animals
All procedures were carried out in accordance with the European
Communities Council, directive 86/609/EEC. Special care was taken to
minimize animal suffering. Female Wistar rats in proestrus were mated
during the night, and d 0 of fetal age was considered the following
morning if spermatozoa were found in a vaginal frotis. To induce fetal
and neonatal hypothyroidism, dams were given 0.02% 2-mercapto-1-
methylimidazole in the drinking water starting from the 12th day after
conception and throughout the whole experimental period including
weaning. This protocol ensures that the animals are hypothyroid during
all the neonatal age, as shown by noticeable physiological landmarks of
hypothyroidism, such as a decreased growth rate, which is clearly ev-
ident from neonatal d 15, and low levels of T4 and T3 (30, 31). N70 rats
are animals between 10 and 12 wk of age. For thyroid hormone treat-
ment, hypothyroid animals were ip injected once daily according to the
following protocols: 1) a high dose of T3 [20 g per 100 g body weight
(BW)] to analyze the kinetics of the response to this hormone and 2) a
more physiological combination of T4 (0.9 g/100 g BW) and T3 (0.2 g
per 100 g BW). The corresponding hypothyroid controls received an
equivalent volume of physiological saline. Two groups of animals re-
ceived ip injections of quinpirole (0.5 mg/kg) or HU210. At the indicated
times, the animals were killed by decapitation, and the brain was quickly
removed, dissected, frozen, and kept at 80 C until used.
Behavioral tests
The motor activity of the animals in an open-field device (100  100
cm) was recorded with a digital video tracking system (SMART; Panlab,
Barcelona, Spain), and the time of immobility and horizontal activity
were analyzed at intervals of 5 min. Twenty-four hours before any drug
treatment, including normalization of thyroid hormone levels, all the
animals remained 10 min in the open field to facilitate context
habituation.
Real-time PCR and Northern analysis
Total RNA was purified according to the method of Chomczynski
and Sacchi (32), and samples (2 g) from the indicated rat brains areas
were used for the synthesis of cDNA with the RETRoscript kit (Ambion,
Austin, Tx). Real-time PCR was performed in an ABI Prism equipment
using the SYBR Green PCR master mix (Applied Biosystems, War-
rington, UK) and 300 nm concentrations of specific primers. The primers
used for the determination of the concentration of the different tran-
scripts were as follows: for CB1 receptor, two different sets of primers
were used (set 1, AAG GAC CTG AGA CAT GCT TTC and CAG TCT
GAG TCC CCC ATG CT and set 2, GGA CTC AAG ATG CTGGAG GAT
and TGT AGG ATG AGG CTG GCA ATT), which synthesized fragments
of 88 and 90 bp, respectively (13). Equal results were obtained with both
sets of primers, suggesting that they recognize the same mRNA. For the
c-fos mRNA we used the following primers: TTT CTC TTT CTC CTT
AGT CTT CTC ATA GC and TCC AGC ACC AGG TTA ATT CCA,
which synthesized a 76-bp fragment (33). For the normalization of cDNA
loading in the PCR, we ran for all the samples parallel reactions am-
plifying the 18S rRNA or the cyclophilin A mRNA, a gene whose ex-
pression does not change with the thyroidal state of the animal (31, 34).
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Primers were CCA GTA AGT GCG GGT CAT AAG C and CCT CAC
TAA ACC ATC CAA TCG G (18S rRNA) and GGC AAG TCC ATC TAC
GGA GAG A and GCC AGG ACC TGT ATG CTT CAG (cyclophilin A)
that synthesize a fragment of 92 and 65 bp, respectively (35, 36). In all
runs, melting curves were performed to make sure that only the cor-
responding DNA fragment was amplified. Each RNA sample was re-
verse transcribed at least one time with oligo-dT and one time with
pd(N)6 random hexamer and each specific sequence measured at least
twice in triplicate. In adult control striatum, random primer cDNA
(dilution 1:10) gave cycle threshold values of around 20, 19, and 23 for
CB1 receptor, cyclophilin A, and c-fos transcripts, respectively. In the case
of 18S rRNA, a dilution of 1:1000 gave cycle threshold values between
20 and21. Northern analyses were performed as previously described
(31) using a labeled rat CB1 receptor probe expanding from nt 89 to 3876
(13).
[3H]SR141716A-binding assay
Membranes from different parts of the brain were prepared as pre-
viously described (37), resuspended in buffer B [HEPES 20 mm (pH 7.4)
and MgCl2 1 mm] and stored at 80 C until use. Radioligand binding
was initiated by the addition of 25 g of protein to tubes containing 0.5
ml of buffer C (buffer B plus fatty acid free BSA 0.5%) and
[3H]SR141716A (2.5 nm) and incubated at 30 C during 90 min. The
reaction was stopped with ice-chilled buffer C and rapidly filtered
through GF/C filters (Whatman, Brentford, Middlesex, UK) (37). Non-
specific binding was assessed in the presence of 5  107 m cold
SR141716A.
[35S]GTPS-membrane binding assay
Frozen membranes were thawed and 7g of proteins were incubated
at 30 C for 20 min in buffer D [50 mm Tris-HCl, 10 mm MgCl2, 1 mm
EDTA, 100 mm NaCl, 60 m GDP, 0.2 mg/ml BSA and 50 m phenyl-
methylsulfonyl fluoride (pH 7.4)]. CB1 receptor agonist was added to-
gether with [35S]GTPS (0.05 nm) and further incubated at 30 C during
1 h. Reaction was stopped with ice-cold buffer E [50 mm Tris-HCl, 10 mm
MgCl2, 1 mm EDTA, 100 mm NaCl, 0.5% BSA (pH 7.4)] and rapidly
filtered through Whatman GF/C filters. Nonspecific binding was de-
termined in the absence of CB1 receptor agonist and the presence of 10
m unlabeled GTPS.
Western blot analysis
Tissues were homogenized in radioimmunoprecipitation assay
buffer, and equal quantities of total protein were separated by 10%
SDS-PAGE and transferred to nitrocellulose membranes, and Western
analysis was performed with primary anti CB1 receptor (Alexis Bio-
chemicals, Lausen, Switzerland) and anticyclophilin A polyclonal anti-
bodies (Calbiochem, San Diego, CA).
Statistical analysis
Data were analyzed by ANOVA, followed by Newman-Keul’s test as
post hoc or Student t test. Statistical significance was considered when
P  0.05.
Results
Motor activity
We first determined motor activity in open field in control
and hypothyroid N70 rats. As shown in Fig. 1A, the loco-
motor score in control rats, as expected, decreases with time.
In contrast, in the hypothyroid group, barely any decrease in
locomotor activity with time was observed, indicating a lack
of habituation and a hyperactivity-like pattern. Cumulative
scores showed a 2-fold increase in the number of crossings
in the hypothyroid group, compared with controls. The do-
paminergic D2 agonist, quinpirole, further increased hori-
zontal locomotion in both groups of animals. In the hypo-
thyroid group, the number of crossings increases 5-fold
between 5 and 120 min, in comparison with controls, in
which only a 2-fold increase was observed (Fig. 1B). These
results suggest that the activity of the endocannabinoid sys-
tem could be decreased in the hypothyroid animals because
it is well established that this system reduces dopaminergic-
induced hyperactivity (14, 15).
Effect of hypothyroidism on the expression of CB1
receptor gene
We first determined whether hypothyroidism has any
effect on the expression of CB1 receptor gene in the brain
of developing animals. For that purpose, the content of
CB1 receptor transcripts and [
3H]SR141716A binding were
determined in different areas of the brain of control and
hypothyroid 15-d-old rats (N15). At this age the effects of
thyroid hormone deficiency on gene expression in the
brain are most evident and they are dependent of the
specific brain area analyzed (38). As shown in Fig. 2A, in
FIG. 1. Congenital hypothyroidism increases locomotor activity. A,
Locomotor activity was analyzed in open field in 70-d-old control (C)
and congenitally hypothyroid (Tx) male rats. B, Effect of quinpirole
administration. Cumulative score is the summation of crossings at all
the indicated times. The results are the average of determinations in
at least 10 different animals, and the bars represent SEs. *, P  0.05;
**, P  0.01 vs. the corresponding control.
Asu´a et al. • T3 Regulates CB1 Receptor Gene Endocrinology, May 2008, 149(5):2657–2666 2659
 by on June 7, 2010 endo.endojournals.orgDownloaded from 
control animals the highest amount of CB1 receptor tran-
scripts were found in the striatum and cerebellum, fol-
lowed by the cerebral cortex and hippocampus. The lowest
concentration was observed in the thalamus, midbrain,
and brain stem. Relative to the effect of hypothyroidism,
a significant decrease on CB1 receptor mRNA levels (49%
of controls) in the striatum and a slight increase in the
hippocampus of hypothyroid animals were observed.
Next, we determined the specific binding of
[3H]SR141716A in membranes prepared from the same
brain areas of control and hypothyroid N15 rats. As shown
in Fig. 2B, differences between control and hypothyroid
animals were observed in the cerebellum and midbrain but
not the other areas analyzed. The lack of differences in
binding observed in the hippocampus is in contrast with
the moderate increase detected in the amount of CB1 re-
ceptor transcripts. In the cerebellum and midbrain of hy-
pothyroid rats, [3H]SR141716A binding was only 80 and
74% of the control values. This effect of hypothyroidism is
apparently in contrast with its lack of effect on the content
of CB1 receptor transcripts in the same areas. However, in
the midbrain, the decrease in [3H]SR141716A binding in
hypothyroid animals can be explained by the decrease
in the number of CB1 receptor transcripts observed in the
striatum of the same animals. On the other hand, the
described discrepancies between binding and the levels of
transcripts observed in the cerebellum and hippocampus
of hypothyroid neonates suggest a complex action of thy-
roid hormone on the expression of this gene.
In view of the previous results showing a decrease in
CB1 receptor mRNA in the striatum and a decrease in
[3H]SR141716 binding in the midbrain and cerebellum of
hypothyroid 15-d-old animals, we next analyzed the de-
velopmental profile of CB1 receptor gene expression in
these areas. In the striatum of control animals, the amount
of CB1 receptor transcripts increased after birth (8-fold
from N5 to N15) (Fig. 3A). This increase was markedly
reduced in hypothyroid animals, and therefore, significant
differences were observed between control and hypothy-
roid rats from N15 to adult life (Fig. 3A). Regarding
[3H]SR141716A binding in the striatum of control animals,
a 2.6-fold increase was observed between N15 and N70 in
contrast with the earlier increase detected in transcripts
levels (Fig. 3A). These results suggest a higher efficiency
of translation or a longer half-life of the receptors in the
adult animals, compared with N15. In agreement with the
observed decrease in the level of transcripts, a clear re-
duction in [3H]SR141716A binding was observed in striatal
(Fig. 3A) and midbrain membranes (Fig. 3B) isolated from
both N30 and N70 hypothyroid animals. In contrast, the
lack of effect of thyroid hormone on transcript number
observed in N15 midbrain was also observed in N70 (Fig.
3B). In the cerebellum, no effect of thyroid hormone on CB1
receptor mRNA content was observed (Fig. 3C). In con-
trast, the binding of [3H]SR141716A to cerebellar mem-
branes was decreased in N30, as previously observed for
N15, although no differences were observed at N70, in-
dicating that the effect of hypothyroidism was transient
and occurred at a posttranscriptional level (Fig. 3C).
We next tested the response of hypothyroid animals to
the acute injection of T3 (20 g per 100 g BW). As can be
observed in Fig. 4A, the administration of T3 rapidly in-
creases the content of CB1 receptor mRNA in the striatum
of N15 and N70 hypothyroid rats. In the neonates, 12 h
after the administration of T3, the content of transcripts is
similar to the one observed in the control animals, and
after 72 h these values were twice that of the control
animals. Similar results were obtained with N70 animals,
indicating a rapid response of this gene to thyroid hor-
mone administration. This response to T3 administration
correlates with the changes observed in binding in the
striatum and mid brain (Fig. 4B) of N30 hypothyroid rats
after the administration of the hormone.
To further substantiate these results, we next analyzed the
mRNA and protein levels of CB1 receptor in the striatum by
Northern and Western blot analysis, respectively, in N70
animals. As shown in Fig. 5, a clear decrease in the amount
of mRNA was observed in the striatum of hypothyroid rats.
In contrast, in the midbrain the levels of CB1 receptor mRNA
FIG. 2. Effect of hypothyroidism on CB1 mRNA content and
[3H]SR141716A binding. A, CB1 receptor transcript content in dif-
ferent brain regions of control (C) and hypothyroid (Tx) 15-d-old rats
(N15). The relative abundance of CB1 transcripts was normalized to
the 18S rRNA signal and is expressed relative to the value in the
cerebral cortex of N15 controls. B, Binding of [3H]SR141716A to mem-
brane fractions isolated from the same brain regions as in A. Values
are the average of triplicate determinations in at least five different
samples, and the bars represent the SEs. *, P  0.05; **, P  0.01 vs.
the corresponding control.
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were lower than in the striatum, and no differences between
control and hypothyroid animals were found (Fig. 5A). Also,
a lower amount of CB1 receptor protein was detected in
hypothyroid striatum (Fig. 5C). All these results are in agree-
ment with the RT-PCR and ligand binding results. No
changes in ligand affinity were detected when control and
hypothyroid membranes were compared (dissociation con-
stant 0.9 0.2 and 0.91 0.15 nm in control and hypothyroid
animals, respectively, data not shown).
Response to cannabinoid agonists
The results presented so far suggest that the striatum of
hypothyroid animals could be less sensitive to the action of
cannabinoids than control animals. We tested this hypothesis
by determining the induction by WIN55212–2 of GTP bind-
ing to G proteins in striatal membranes isolated from N70
control and hypothyroid rats. We also analyzed the response
to HU210 of the immediate response gene c-fos in both
groups of animals. As shown in Fig. 6A, a lower GTP binding
response to WIN55212–2 (3 108 and 105m) was observed
in hypothyroid membranes (69% of the control values). This
decrease in GTP binding was observed with all the concen-
tration tested (Fig. 6B), and a similar EC50 (0.9 0.12 10
7 m
FIG. 3. Effect of hypothyroidism on the developmental profile of CB1
receptor gene expression in the striatum, midbrain, and cerebellum.
Total RNA and membranes were isolated from striatum (A), midbrain
(B), and cerebellum (C) of control (C) and hypothyroid (Tx) rats at the
indicated ages and the amount of CB1 receptor transcripts and
[3H]SR141716A binding determined. The relative abundance of CB1
transcripts was normalized to the 18S rRNA signal and is expressed
relative to the value in N15 controls. Values are the average of trip-
licate determinations in at least five different samples, and the bars
represent the SEs. *, P  0.05; **, P  0.01; ***, P  0.001 vs. the
corresponding control.
FIG. 4. T3 induces the expression of the CB1 receptor gene. Hypo-
thyroid rats (N15, N30, and N70) were injected with T3 (20 g per
100 g BW) and killed at the indicated times. Total RNA from the
striatum (N15 and N70; A) and membranes from the striatum and
midbrain (N30; B) were isolated and CB1 receptor mRNA content and
[3H]SR141716A binding determined. The relative abundance of CB1
transcripts was normalized to the cyclophilin A signal and are ex-
pressed relative to the values in the age-matched euthyroid controls.
Values are the average of triplicate determinations in at least five
different samples, and the bars represent the SEs. *, P 0.05; **, P
0.01; ***, P 0.001 vs. the hypothyroid values. Gray bands represent
the mean values  SE of control (euthyroid) animals.
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and 0.92  0.14 107 m) was obtained for both control and
hypothyroid membranes. These results are clearly in agree-
ment with the lower number of CB1 receptors observed in the
hypothyroid animals.
As commented above, we also analyzed the induction of
the early gene c-fos by the cannabinoid receptor agonist
HU210. The time course of c-fos gene in response to HU210
in the striatum and cerebellum of N70 control and hypo-
thyroid animals is shown in Fig. 7. In the striatum of
control animals (Fig. 7A), a rapid a transient increase (3-
fold) was observed 30 min after administration of the drug,
which was completely absent in hypothyroid rats. On the
contrary, in the cerebellum, in which no differences in CB1
receptor content were observed between N70 control and
hypothyroid animals, the same response was observed in
both groups after the injection of the cannabinoid.
Based on the biochemical results described above, it
could be anticipated that the hypothyroid animals are less
responsive to cannabinoid treatment. To test this hypoth-
esis, we studied the inhibition of locomotor activity
in response to HU210 in control and hypothyroid animals.
As shown in Fig. 8, HU210 clearly decreased locomotor
activity in the control group but not the hypothyroid
group.
Effect of thyroid hormone treatment
As shown before in the kinetic studies, T3 injection increased
CB1 receptor gene expression in the hypothyroid animals in a
relatively short time, suggesting that thyroid hormone could
also normalize the biochemical and behavioral parameters an-
alyzed in this study. To verify this premise, N70 hypothyroid
rats were injected with physiological doses of thyroid hormones
and, after 5 d of treatment, biochemical and behavioral param-
eters were analyzed. This treatment, as expected, normalized
the CB1 receptor mRNA in the striatum of hypothyroid animals
(Fig. 9A). In accordance with the normalization of CB1 receptor
mRNA content, the response of the c-fos gene to cannabinoid
administration was also normalized in the striatum of hypo-
thyroid animals treated with thyroid hormones, as shown by
the transient 3-fold increase observed in c-fos transcript content
(Fig. 9B). Finally, horizontal locomotor activity was clearly de-
creased by this treatment (Fig. 9C), and the behavioral response
to cannabinoid agonist was restored in treated animals as
shown by the appearance of typical motor inactivity in response
to HU210 (Fig. 9D).
FIG. 5. Hypothyroidism decreases CB1 receptor mRNA and protein con-
tent. A, Total RNA was extracted from striatum and midbrain of control
(C) and hypothyroid (Tx) N70 rats and the content of CB1 receptor
mRNA was measured by Northern analysis, as indicated in Materials
and Methods. B, The same blot stained with methylene blue for RNA
loading control. C, Membranes were isolated from the striatum of control
(C) and hypothyroid (Tx) N70 rats, and the amount of CB1 receptor
protein was determined by Western blot analysis, as indicated in Ma-
terials andMethods. D, Same blot probed with a cyclophilin A antibody.
FIG. 6. Hypothyroidism decreases cannabi-
noid agonist-stimulated [35S]GTPS bind-
ing to striatal membranes. A, Membranes
were isolated from the striatum of control
(C) and hypothyroid (Tx) N70 rats and the
effect of WIN 55212–2 on [35S]GTPS bind-
ing determined. Values are the average of
triplicate determinations in at least six dif-
ferent samples, and the bars represent the
SDs. *, P  0.05 and **, P  0.01 vs. the
corresponding hypothyroid value. B, Repre-
sentative curve of full range agonist concen-
trations on [35S]GTPS binding in striatal
membranes of control and hypothyroid N70
rats.
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Discussion
In this work we analyzed the role of the endocannabinoid
system in the hyperactive phenotype observed in congeni-
tally hypothyroid animals. Our results clearly show that the
postnatal increase in CB1 receptor gene expression in the
basal ganglia circuitry of control rats is thyroid hormone
dependent. Thus, lower levels of CB1 receptors and a lower
biochemical and behavioral response to cannabinomimetic
drugs were observed in adult congenitally hypothyroid an-
imals. These changes correlate with higher spontaneous and
dopaminergic-induced locomotor activity. Because it is gen-
erally accepted that the endocannabinoid system in the basal
ganglia circuitry acts as a brake in motor activity initiation
(11, 15), these results suggest that the CB1 receptor gene could
be an important mediator in this phenotypic manifestation of
hypothyroidism, as suggested in a former study in juvenile
spontaneous hypertensive rats, a putative model of attention
deficit hyperactivity disorder (14).
In humans, the clearest correlation between dysthyroid-
ism and hyperactivity comes from studies with RTH pa-
tients, which inherit a mutant form of the TR gene (18, 39,
40). The mutated protein has normal DNA binding activity
but lower T3 binding and transactivation capabilities and
antagonizes the function of normal receptors in a dominant
negative manner (41). RTH patients have elevated levels of
thyroid hormones and usually they are in an euthyroid or
mildly hypothyroid metabolic state, yet also symptoms of
hyperthyroidism can be observed in specific organs, prob-
ably as a consequence of the different levels of expression of
TR isoforms in the different tissues (42). Thus, it is unclear
whether the hyperactivity of these individuals is the conse-
quence of hypo- or hyperthyroidism. In this regard, different
observations (19, 43–46) indicate that the administration of
supraphysiological doses of thyroid hormone, and particu-
larly the use of high affinity ligands of the TR isoform, such
as triiodothyroacetic acid (47), could be beneficial for reduc-
ing hyperactivity in these individuals (44, 45), suggesting
that the brain of these patients is in a hypothyroid state.
Consisting with these results, a long-term prospective study
reported a high rate of ADHD in children from areas of
moderate iodine deficiency (48). These results are in agree-
ment with the biochemical and behavior data presented here,
showing that congenitally hypothyroid animals are hyper-
active and that they significantly improved after thyroid
hormone administration.
Also, in experimental animals, transient perinatal hypo-
thyroidism is associated to motor hyperactivity and other
ADHD symptoms in the adult life (21–24). However, in con-
genitally hypothyroid rats, conflicting results have been pub-
lished. In line with the data presented here, Overstreet et al.
(25) have shown increased locomotor activity in iodine-de-
ficient congenitally hypothyroid rats. In contrast, other au-
thors did not find any increase in motor activity (26). In the
hyt/hyt mouse model of hypothyroidism, no changes in
motor activity have been reported (49). The causes under-
lying this apparent contradiction are unclear. Although the
hyt/hyt model is not entirely comparable with the one we
used here, the experimental model used by Sala-Roca et al.
(26) is essentially the same. One possible explanation is that
the degree of hypothyroidism in the animals used in the
study of Sala-Roca et al. could be very low or almost negli-
gible during the critical developmental period because, as
they point out, their animals grew normally during the first
5 wk of postnatal life. In this regard it is known that hyper-
activity is a phenotypic manifestation of perinatal hypothy-
roidism, but it is not observed when adult rats are made
hypothyroid (data not shown). Interestingly, and in agree-
ment with the data obtained from the study of human RTH,
when a mutated human TR (TRPV) is expressed in mice
by transgenic or knockin techniques, male animals become
clearly hyperactive (50, 51).
Additionally, our data show that both hyperactivity and
the abnormal response of the endocannabinoid system found
in hypothyroid animals are clearly improved by physiolog-
FIG. 7. Hypothyroidism decreases HU210 induction of c-fos gene in
the striatum but not the cerebellum. Total RNA was extracted from
striatum (A) and cerebellum (B) of control (C) and hypothyroid (Tx)
N70 rats injected with vehicle or HU210 (50 g/kg BW), killed at the
indicated times, and the amount of c-fosmRNA measured by RT-PCR.
The relative abundance of c-fos transcripts was normalized to the
cyclophylin A signal and expressed relative to the values at time 0.
Values are the average of at least four different samples, and the bars
represent the SEs. *, P  0.05; **, P  0.01 vs. the value at time 0.
FIG. 8. Hypothyroidism decreases behavioral response to the canna-
binoid agonist HU210 (HU). Control (A) and hypothyroid N70 (B)
male rats were injected with vehicle or HU210 (10 g/kg) and motor
activity determined as indicated. The results are the average of the
values obtained in at least 10 different animals, and the bars repre-
sent SEs. *, P  0.05 vs. the corresponding control.
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ical doses of thyroid hormones, suggesting that the brain
response to these hormones, in this particular system, is
maintained in adult congenitally hypothyroid rats. The rea-
sons that in the transient model of perinatal hypothyroidism
(21–24), the hyperactive phenotype remains despite thyroid
hormone normalization are unclear. However, there are
many reports suggesting that perinatal manipulation of the
endocannabinoid system with drugs leads to permanent
changes in its functionality, resulting, among others, in hy-
peractivity (52), altered emotional responses (53), and mem-
ory deficits (54).
The CB1 receptor is broadly expressed in the brain; how-
ever, we show here that it is mainly in the basal ganglia in
which its expression is targeted by thyroid hormones. In
contrast, in other areas of the brain, known to contain active
thyroid hormone receptors, no effect or even an opposite
effect of thyroid hormone on the expression of the CB1 re-
ceptor gene was observed (Fig. 2). These apparently contra-
dictory results are in agreement with many reports showing
that the action of thyroid hormones on gene expression in the
developing brain is especially dependent on the age and the
brain area analyzed (38, 55). The molecular bases for this
variability in thyroid hormone action are not clear, although
it is well established that, in addition to the receptors, many
other different proteins are required for gene regulation by
thyroid hormones (56).
Our results are in agreement with those reported by other
authors showing an inverse relationship between the activity
of the endocannabinoid system and locomotor activity. The
administration of cannabinoid agonists and inhibitors of
anandamide and 2-arachidonoylglycerol uptake reduce hy-
peractivity in spontaneously hypertensive rats (14, 57) and
hyperactivity induced by psychostimulants and D2 agonists
(58). On the other hand, CB1 receptor antagonists favor do-
pamine receptor-mediated induction of motor activity (15)
and stereotyped behaviors (59). Impulsive spontaneously
FIG. 9. Thyroid hormone administra-
tion recovers biochemical and behav-
ioral parameters in hypothyroid rats. A,
The CB1 receptor transcript content
was determined in the striatum of N70
control (C), hypothyroid (Tx), and hy-
pothyroid rats injected with physiolog-
ical amounts of T4 and T3 during 5 d
(T4/T3). The relative abundance of CB1
transcripts was normalized to the cy-
clophilin A signal and represented rel-
ative to the values in the corresponding
controls. Values represent the average
of the values obtained in at least five
different animals, and the bar repre-
sent the SE. B, T4/T3-treated rats were
injected with HU210 (10 g/kg), killed
at the indicated times, total RNA ex-
tracted from the striatum, and c-fos
mRNA content determined. Values rep-
resent the average of at least five dif-
ferent animals, and the bar represent
the SE. C, Motor activity was deter-
mined in Tx and T4/T3 male rats, as
indicated in Materials and Methods.
Values represent the average of at least
10 animals, and bars are the SE. D,
otor activity was determined in T4/T3
rats injected with vehicle or HU210 (10
g/kg). Values are the average of at
least 10 animals, and bars represent the
SE. *, P  0.05 vs. the corresponding
control.
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hypertensive rats have lower levels of CB1 receptors in the
prefrontal cortex (57). Also, in reserpine-treated rats, an an-
imal model of Parkinson’s disease, an increase in 2-AG has
been described in the globus pallidus, which has been related
to the suppression of locomotion in these animals, and CB1
receptor antagonists are required for a better normalization
of motor activity (60). These results may apparently be in
contradiction with the lack of a similar phenotype in can-
nabinoid CB1 receptor knockouts. However, although these
animals are not hyperactive, they display abnormal dopam-
ine-mediated behavior such us acquisition of operant re-
sponding for cocaine and opiates (61). Moreover, the selec-
tive reduction of CB1 receptors exhibited by hypothyroid rats
with the global lack of CB1 receptors in different species and
throughout the whole developmental period cannot be fully
compared.
Collectively, our results suggest, but do not unequivocally
show, that a deficit in the endocannabinoid system function
in the basal ganglia could cause, at least in part, the motor
hyperactivity associated with the congenital hypothyroid
state, and open new research expectations in ADHD.
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